Ipo

‘Massachusetts remains in a position of strength to receive continued, meaningful investment’

07-Feb-2023 By Rachel Arthur

Around 25% of US venture capital biopharma investments flowed to Massachusetts in 2022: cementing the state’s position as a leader in the industry. But how will economic uncertainty affect the hub’s fortunes moving forward?

Biotech Absci sees shares soar in IPO debut

27-Jul-2021 By Jane Byrne

Absci Corp, a Vancouver, Washington headquartered synthetic biology company developing technologies to accelerate drug discovery, has gone public.

Teva spinout eyes outsourced manufacturing scale up after $85M IPO

21-Nov-2019 By Nick Taylor

89bio plans to invest up to $10m (€9m) in manufacturing and scale up, after raising $85m in an upsized IPO.

Avantor wraps up $2.9bn IPO, looks to biopharma for growth

22-May-2019 By Nick Taylor

Avantor has raised $2.9bn through an initial public offering ahead of a planned expansion of its biopharma product line.

Biologics company sells shares, registers with SEC

04-Jan-2019 By Maggie Lynch

Harpoon offers to sell shares of its common stock in its proposed IPO after registering a statement with the SEC while developing T-Cell engagers.

Orchard Therapeutics plans to go public to raise $172m

17-Oct-2018 By Maggie Lynch

Orchard will launch an IPO on the Nasdaq Stock Market to raise $172m to fund research and development.

Nearly half of investments into biotech industry generated by Massachusetts

05-Sep-2018 By Ben Hargreaves

On the eve of Boston Biotech Week, a report was released by MassBio that claimed 48% of all biotech investment in 2017 was accounted for by Massachusetts-based companies.

Biotech investment reaches fever pitch, but will it last?

20-Aug-2018 By Ben Hargreaves

Biotech M&A started off a bang this year and as the first half of the year has drawn to a close, biotech IPOs have reached a number that could see 2018 become a record-breaker.